Romosozumab
Evenity (romosozumab) is an antibody pharmaceutical. Romosozumab was first approved as Evenity on 2019-04-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis. The pharmaceutical is active against sclerostin.
| Trade Name | Evenity |
|---|---|
| Common Name | Romosozumab |
| Indication | osteoporosis, postmenopausal osteoporosis |
| Drug Class | Monoclonal antibodies: humanized, bone target |
